Biological products refer to drugs prepared from microorganisms, cells, various animal and human tissues, liquids, and other biological materials obtained through ordinary or biotechnology such as genetic engineering, cell engineering, protein engineering, enzyme engineering, and protein crystallization, used for human disease prevention, treatment, and diagnosis.

Equine biological products usually refer to related biological products derived from horses, which may include various biological preparations such as horse serum, horse plasma, and horse immunoglobulin. These products may be used in multiple fields such as healthcare, scientific research, and vaccine production, depending on their characteristics and application scenarios.

Overview of Overall Market Development

In recent years, with the intensification of population aging and changes in the disease spectrum, the demand for equine biological products has been increasing. For example, there will be greater market demand for equine biological products used for the treatment of cancer, cardiovascular disease, neurodegenerative diseases, etc. The data shows that the total market revenue of global equine biological products is estimated to be $1253 million in 2024, an increase of 7.32% compared to 2023, and is expected to continue to increase to $1868 million by 2029.

Segmented Market Analysis

According to their different functional roles, equine biological products can usually be divided into three types: preventive equine biological products, therapeutic equine biological products, and diagnostic equine biological products. Preventive equine biological products refer to equine biological products that can enhance the body's immunity after vaccination, such as vaccines, toxoids, and antitoxins; Therapeutic equine biological products refer to equine biological products that can be used to treat certain diseases, such as various blood products, immune preparations, and gene therapy drugs; Diagnostic equine biological products refer to equine biological products used for diagnosing a certain disease, such as various testing reagents, antibodies, and enzymes. Among them, preventive equine biological products occupy the largest market share, with an estimated 40.36% in 2024.

From the perspective of application sites, equine biological products are mainly used in hospitals, clinics, and diagnostic centers. Among them, hospitals hold the highest share, estimated to be 55.91% in 2024.

 

Source: www.globalmarketmonitor.com

Analysis of Market Development in Major Regions

Research shows that Europe and North America are the top and second largest revenue markets in the industry, respectively. The data shows that in 2024, the revenue of the European and North American equine biological product markets is estimated to be $444 million and 434 million respectively, with revenue shares estimated to be 35.40% and 34.60%, respectively; The Asia Pacific market is expected to rank third with a market revenue of $276 million and a market share of 21.99%.

Global Equine Biological Product Market Revenue and Market Share by Region Forecast in 2024

Regions	Market Revenue (Million USD)	Share
North America	434	34.60%
Europe	444	35.40%
Asia Pacific	276	21.99%
South America	58	4.60%
Middle East & Africa	43	3.41%

Market Development Trend Analysis

Innovation-driven: With the continuous progress of biotechnology, new equine biological products continue to emerge, providing a continuous source of power for market growth. In the coming years, emerging fields such as gene therapy and cell therapy will become the main driving force for market growth.

Improvement of regulatory environment: Governments around the world are strengthening the regulatory construction of equine biological products and raising market access barriers, which will be conducive to the standardized development of the market. Meanwhile, the strengthening of international cooperation and exchanges will also create a better external environment for market development.

Technological progress: The advancement of biotechnology has provided a better means for the research and production of equine biological products. For example, gene editing technology, cell immunotherapy technology, etc. will provide strong support for the innovation of equine biological products.

Cost reduction: With the expansion of production scale and technological progress, the production cost of equine biological products will gradually decrease, which will be conducive to further popularization and development of the market.